We are live on ! Find out more
IMMX icon

Immix Biopharma
IMMX

8 hedge funds and large institutions have $352K invested in Immix Biopharma in 2022 Q1 according to their latest regulatory filings, with 7 funds opening new positions, increasing their positions, 1 reducing their positions, and 9 closing their positions.

New
Increased
Maintained
Reduced
Closed

18.36% less ownership

Funds ownership: 20.3% → 1.93% (-18%)

22% less first-time investments, than exits

New positions opened: 7 | Existing positions closed: 9

27% less funds holding

Funds holding: 11 → 8 (-3)

94% less capital invested

Capital invested by funds: $5.47M → $352K (-$5.12M)

100% less repeat investments, than reductions

Existing positions increased: 0 | Existing positions reduced: 1

Holders
8
Holders Change
-3
Holders Change %
-27.27%
% of All Funds
0.13%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
7
Increased
–
Reduced
1
Closed
9
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Renaissance Technologies
Renaissance Technologies
New York
+$232K
2
VF
Virtu Financial
New York
+$87.3K
3
ICG
InterOcean Capital Group
Tennessee
+$59K
4
XT
XTX Topco
Cayman Islands
+$48.2K
5
BlackRock
BlackRock
New York
+$35K

Top Sellers

Rank Fund Capital Flow
1
M
Murchinson
Ontario, Canada
-$2.48M
2
LCM
Lynwood Capital Management
Ontario, Canada
-$2.01M
3
ACM
Altium Capital Management
New York
-$436K
4
UBS Group
UBS Group
Switzerland
-$116K
5
EVC
Eidelman Virant Capital
Missouri
-$103K
Name Holding Trade Value Shares
Change 		Change in
Stake
Renaissance Technologies
1
Renaissance Technologies
New York
$151K +$232K +62,600 New
VF
2
Virtu Financial
New York
$57K +$87.3K +23,515 New
Citadel Advisors
3
Citadel Advisors
Florida
$52K -$17.7K -4,761 -18%
ICG
4
InterOcean Capital Group
Tennessee
$38K +$59K +15,900 New
XT
5
XTX Topco
Cayman Islands
$31K +$48.2K +12,992 New
BlackRock
6
BlackRock
New York
$22K +$35K +9,415 New
Osaic Holdings
7
Osaic Holdings
Arizona
$1K +$1.3K +350 New
M
8
Murchinson
Ontario, Canada
– -$2.48M -695,600 Closed
LCM
9
Lynwood Capital Management
Ontario, Canada
– -$2.01M -565,297 Closed
ACM
10
Altium Capital Management
New York
– -$436K -122,388 Closed
UBS Group
11
UBS Group
Switzerland
– -$116K -32,649 Closed
EVC
12
Eidelman Virant Capital
Missouri
– -$103K -29,856 Closed
Millennium Management
13
Millennium Management
New York
– -$73K -20,470 Closed
TSS
14
Two Sigma Securities
New York
– -$47K -13,173 Closed
CCM
15
Context Capital Management
California
– -$41K -11,532 Closed
CS
16
Clear Street
New York
– -$4K -1,000 Closed
Wells Fargo
17
Wells Fargo
California
– +$97 +26 New

IMMX Hedge Fund Activity: Q1 2022 in Review

8 of the 6,341 institutional investors tracked by Wall St. Rank reported a position in Immix Biopharma (IMMX) for Q1 2022, worth a combined $352K — down 94% from $5.47M a quarter earlier.

Sellers outnumbered buyers: 9 funds closed out of IMMX and 7 opened new positions — a net loss of 2 holders — while 1 trimmed existing stakes and 0 added.

The largest buyer was Renaissance Technologies, opening a new position worth an estimated $232K. The largest seller was Murchinson, exiting entirely with an estimated $2.48M sold.

  • 8 institutional investors held Immix Biopharma (IMMX) as of Q1 2022, down from 11 in Q4 2021.
  • Funds reported $352K of Immix Biopharma stock for Q1 2022, down 94% quarter-over-quarter.
  • 7 funds opened new Immix Biopharma positions in Q1 2022 and 9 closed out, a net change of -2 holders.
  • The largest Immix Biopharma buyer in Q1 2022 was Renaissance Technologies, an estimated $232K added.
  • The largest Immix Biopharma seller in Q1 2022 was Murchinson, an estimated $2.48M sold.

Based on aggregated 13F filings for Q1 2022.